Overall, we have identified a specific CD8+T cell subgroup demonstrating a high level of anti-tumor ability within TLS, which unveiled the underlying mechanisms of TLS-mediated tumor-killing immunity and possessed promising clinical implications such as adoptive cell therapy (ACT). The gene discussed is CD8A; the disease is neoplasm.